Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tranexamic acid in oncology

A H Seto1, D S Dunlap

  • 1Medical University of South Carolina, Charleston 29425, USA.

The Annals of Pharmacotherapy
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Tranexamic acid may help prevent bleeding in cancer patients, particularly those with acute promyelocytic leukemia (APL). While generally safe, more research is needed to confirm its effectiveness in broader oncology populations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The lupus susceptibility locus Sle3 is not sufficient to accelerate atherosclerosis in lupus-susceptible low density lipoprotein receptor-deficient mice.

Lupus·2009
Same author

Continuous fentanyl infusion: use in severe cancer pain.

The Annals of pharmacotherapy·1998
Same journal

Association Between Prior PARP Inhibitor Maintenance Therapy and Myelosuppression During Subsequent Chemotherapy in Ovarian Cancer.

The Annals of pharmacotherapy·2026
Same journal

Prolonged Response to Nivolumab in Metastatic Vulvar Carcinoma: Should Immunotherapy be Continued and for How Long? A Debatable Issue!

The Annals of pharmacotherapy·2026
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Hemorrhagic complications are a significant concern in oncology patients.
  • Enhanced fibrinolysis is a characteristic of certain hematologic malignancies like acute promyelocytic leukemia (APL).

Purpose of the Study:

  • To evaluate tranexamic acid as a potential adjunct for preventing bleeding in cancer patients.
  • To assess the safety and potential efficacy of tranexamic acid in managing hemorrhagic risks in oncology.

Main Methods:

  • Review of existing studies and case reports on tranexamic acid use in oncology.
  • Analysis of data regarding bleeding prophylaxis and adverse events.

Main Results:

  • Tranexamic acid suggests potential for bleeding prophylaxis in APL due to enhanced fibrinolysis.

Related Experiment Videos

  • Administration was found to be safe with minimal adverse effects and no thromboembolic events.
  • Efficacy in the broader thrombocytopenic oncology population remains undetermined due to study limitations.

    • Conclusions:

    • Tranexamic acid may be a viable option for bleeding prophylaxis in specific oncology subsets like APL.
    • Further large-scale, controlled clinical trials are essential to establish its routine use in the general oncology population.